STI-6129

N/A

Report date: 2024/02/05 13:54:12

Base Information

Drug NameSTI-6129
Drug Alias NameSTI-6129LNDS-1001
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC) > Payload > Duostatin-5.2 payloadBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC)
Mechanisms of ActionCell death stimulantsAnti-CD38
TargetsLymphocyte differentiation antigen CD38
Therapy Area/IndicationsSolid tumoursMultiple MyelomaImmunoglobulin Light-chain Amyloidosis +[5] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesSorrento Therapeutics Inc
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesSorrento Therapeutics IncZhejiang Acea Pharmaceutical Co Ltd
Inactive CompaniesThe University Of Texas MD Anderson Cancer Center +[2] 
Active IndicationsSolid tumoursMultiple MyelomaImmunoglobulin Light-chain Amyloidosis
Inactive IndicationsLeukemia, Myeloid, AcutePrecursor T-Cell Lymphoblastic Leukemia-Lymphoma

Other Information

ATC CodeN/A
Related LinksN/A